Sai-Hong Ignatius Ou, MD, PhD
The treatment of patients with non–small cell lung cancer (NSCLC) was revolutionized with the discovery of targetable mutations more than a decade ago. Although many agents have been approved in the ALK-
positive NSCLC landscape since then, other targets, such as ROS1
are under investigation in a new age of targeted therapies, said Sai-Hong Ignatius Ou, MD, PhD.
alterations. Although it is a 23-gene panel, it can only be used to test for these 3 alterations, based on the FDA’s indication, explained Ou.
-rearrangement was discovered in lung cancer around the same time as ALK
in 2007. This receptor tyrosine kinase fusion is also seen in other tumor types such as brain, breast, soft tissue, skin, stomach, and ovarian cancer. All receptor tyrosine kinase fusions have fusion partners, said Ou, adding that there are about 13 fusions partners established for ROS1.
... to read the full story